COVID-19 Drug Standards for LC-MS/MS
Internal standards for therapeutic drug monitoring of potential COVID-19 drugs
Laboratories and hospitals around the world are carrying out studies to find a solution against COVID-19. Several drugs are on the test bench such as Hydroxychloroquine, Favipiravir or Remdesivir. Used alone or in combination with other drugs, these molecules demonstrate promising results. To develop dosage methods, e.g. to determine optimal doses, clinical studies based on therapeutic drug monitoring by LC-MS will be needed.
Many studies and clinical trials across the USA have been launched to test experimental treatments for COVID-19, including these compounds: Remdesivir, Lopinavir, Ritonavir, and Hydroxychloroquine. Shimadzu and Alsachim are supporting these efforts by providing standard and SIL internal standards for therapeutic drug monitoring of these potential anti-COVID-19 drugs.
|Related Drug||Product Name||Part Number|
Lopinavir and Ritonavir
Remdesivir and GS 441524
(Active Metabolites of Nucleoside
|[13C6]-Remdesivir (Mixture of Diastereoisomers)||ALSA-C8854-1mg|
GS 441524 / CAS 1191237-69-0
|Chloroquine and Hydroxychloroquine||
|[2H5]-Chloroquine oxalate salt||ALSA-C5023-1mg|
|[2H5]-Hydroxychloroquine dioxalate salt||ALSA-C6422-1mg|
|[2H5]-Desethylchloroquine dioxalate salt||ALSA-C2453-1mg|
|Nafamostat Mesylate||Nafamostat Mesylate||ALSA-C8848-1mg|